Gilead CEO pressured on PrEP pricing at House hearing

Critics of Gilead contend it had little to do with the research behind Truvada's use as a preventive therapy — a charge CEO Daniel O'Day rebutted.

Source: Healthcare Dive, https://www.healthcaredive.com